Hydroxychloroquine/chloroquine in patients with COVID-19 in Wuhan, China: a retrospective cohort studyResearch Article Published on 2021-08-122022-10-28 Journal: BMC Infectious Diseases [Category] COVID-19, SARS, [키워드] administration Admission age analyzed Atrioventricular block average Chloroquine clearance COVID-19 COVID-19 pandemic Deceased disease disease severity Dizziness Efficacy and safety evaluate Factor Gender HCQ Hydroxychloroquine identify independent parameter Laboratory later phase less Linear regression analysis management Mortality one patient Patient patients with COVID-19 QTc Result retrospective cohort study RNA selected supplementary material therapeutic agent Treatment treatment group two groups virus Virus shedding periods was performed Wuhan [DOI] 10.1186/s12879-021-06477-x PMC 바로가기 [Article Type] Research Article
Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis코로나19 환자에서 아르비돌(우미페노비르)의 효능 및 안전성: 체계적인 고찰 및 메타분석Review Published on 2021-08-042022-09-10 Journal: Immunity, Inflammation and Disease [Category] SARS, 치료제, [키워드] (Umifenovir 2019 novel coronavirus infection 2019‐nCoV infection 95% confidence interval Adding adverse event Arbidol benefit carried Chloroquine Cochrane Library coronavirus COVID‐19 Day disease Efficacy Efficacy and safety Evidence inclusion criteria Lopinavir Lopinavir/ritonavir mean difference medRxiv Negative conversion no significant difference Novel coronavirus objective Patient PCR Primary outcome Primary outcomes Result risk risk of bia risk ratio Ritonavir secondary outcome Secondary outcomes significant difference systematic review therapeutic agent therapeutic agents therapeutic effect Treatment treatment group umifenovir was performed were used [DOI] 10.1002/iid3.502 PMC 바로가기 [Article Type] Review
Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort StudyImmunology Published on 2021-08-022022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, MERS, [키워드] 95% CI 95%CI Acute kidney injury acute respiratory distress AKI ARDS China confounding factors COVID-19 COVID-19 patient disease severity Efficacy FIVE greater hospital ICU ICU admission in-hospital mortality rate incidence increased risk intensive care intubation rate multicenter cohort study non-recovery Organ failure outcomes paO2/fiO2 Patient patients with COVID-19 performed Primary outcome Result significantly significantly higher SOFA subgroup syndrome the patient therapy thymosin alpha 1 treat treatment group was used [DOI] 10.3389/fimmu.2021.673693 PMC 바로가기 [Article Type] Immunology
An observational cohort study to assess N-acetylglucosamine for COVID-19 treatment in the inpatient settingResearch article Published on 2021-08-012022-10-05 Journal: Annals of Medicine and Surgery [Category] 임상, 치료법, [키워드] Administered administration Admission affected Analysis anti-inflammatory activity Clinical outcome confidence interval control group Coronavirus disease 2019 COVID-19 effective Effects enrolled evaluated Follow-up hospital Hospital mortality Hospitalization ICU ICU admission ICU admission rates immune response IMPROVE independent intensive care intensive care units intubation Length of stay material median age modulate Mortality multivariate Multivariate analysis N-Aceytlglucosamine Observational cohort study Odds ratio Patient Primary outcome reduced Registration Result retrospective secondary outcome significantly lower single-center standard care supplemental oxygen Treatment treatment group Trial Univariate analysis with COVID-19 [DOI] 10.1016/j.amsu.2021.102574 [Article Type] Research article
Fourteen-day survival among older adults with severe infection with severe acute respiratory syndrome coronavirus 2 treated with corticosteroid: a cohort studyObservational Study Published on 2021-08-012022-10-05 Journal: Clinical microbiology and infection : the official [Category] SARS, 임상, [키워드] 95% CI acute respiratory syndrome adverse events Analysis assigned baseline C-reactive protein characteristics of patient cohort study control group coronavirus coronavirus disease Coronavirus disease 2019 Corticosteroid Corticosteroids COVID-19 CT scan died discharged disease Effectiveness elderly France hazard ratio hospital Hospitalized inclusion criteria Infection Inflammatory interquartile range Luxembourg main analysis median age not differ observational study Older oxygen participant Patient PCR-confirmed PCR-confirmed diagnosis Pneumonia Prednisone Primary outcome Probability proportion receiving risk routine care SARS-CoV-2 severe COVID-19 Severe infection significant increase significantly Standard of care survival syndrome Therapeutic evaluation. treated Treatment treatment group Weighting [DOI] 10.1016/j.cmi.2021.03.021 PMC 바로가기 [Article Type] Observational Study
Does Coronavirus Disease 2019 (COVID-19) Affect Perioperative Morbidity and Mortality for Patients Requiring Emergency Instrumented Spinal Surgery? A Single-Center Cohort StudyObservational Study Published on 2021-08-012022-10-05 Journal: World neurosurgery [Category] SARS, 임상, [키워드] Admission age Analysis average BMI body mass index clinical Clinical outcome cohort study Comorbidities comparable Complication complications coronavirus disease correlated COVID-19 Data collection determine discharge Emergency evaluate the effect Factor Fever groups Health Service hospital Hospital stay identify in both group increased risk Instrumented spine surgery (ISS) intensive care major trauma Major trauma center (MTC). morbidity morbidity and mortality Mortality neurologic no difference Occurrence outcome Oxygen requirement oxygen saturation pandemic Patient patients with COVID-19 Perioperative positive postoperative required respiratory infection retrospective cohort study risk factor saturation Sex smoking spinal surgical treatment group United Kingdom was performed was used were recorded with COVID-19 [DOI] 10.1016/j.wneu.2021.06.046 PMC 바로가기 [Article Type] Observational Study
Baidu Jieduan granules, traditional Chinese medicine, in the treatment of moderate coronavirus disease-2019 (COVID-19): study protocol for an open-label, randomized controlled clinical trial중등도 코로나바이러스 질병-2019(COVID-19) 치료에 사용되는 중국 전통 의학 Baidu Jieduan 과립: 공개, 무작위 대조 임상 시험을 위한 연구 프로토콜Study Protocol Published on 2021-07-222022-09-10 Journal: Trials [Category] SARS, 임상, 치료제, [키워드] 1:1 absence Adverse adverse events AEs Antibiotics antiviral medicine applied Baidu Baidu Jieduan granule baseline Chinese circulating clinical Clinical efficacy clinical evidence conducted control group Controlled clinical trial Controlled trial coronavirus coronavirus disease coughing COVID-19 develop Effect effective Efficacy and safety epidemic disease epidemic diseases evaluate event experimental group fatigue Fever Glucocorticoids Granule granules Health moderate Moderate COVID-19 multicentre Open-label outcome Patient patients with COVID-19 Primary outcome Randomized Randomized controlled trial Randomly receive registry resulting Standard therapy Study protocol supplementary material Support Symptom TCM theory Traditional Chinese medicine treating COVID-19 Treatment treatment group treatment initiation Trial twice a day use of antibiotics [DOI] 10.1186/s13063-021-05418-y PMC 바로가기 [Article Type] Study Protocol
Effect of Physician-Delivered COVID-19 Public Health Messages and Messages Acknowledging Racial Inequity on Black and White Adults’ Knowledge, Beliefs, and Practices Related to COVID-19 A Randomized Clinical TrialRandomized Controlled Trial Published on 2021-07-142022-10-04 Journal: JAMA Network Open [Category] SARS, 임상, [키워드] Adults affected age assigned black center clinical Community conducted Control control group control groups COVID-19 COVID-19 knowledge Critical described determine Effect effective Effectiveness eligible evaluate Final finding Gender greater groups Health Importance IMPROVE incidence rate individual information intervention group knowledge less Masks measure message not differ objective participant physician Placebo Point Practice prevention Protective Public randomization randomized clinical trial Randomly receive recorded Registration Relevance Result screened setting social distancing statistically significant Symptoms the disease treatment group Volunteer white women [DOI] 10.1001/jamanetworkopen.2021.17115 PMC 바로가기 [Article Type] Randomized Controlled Trial
Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trialReview Published on 2021-07-102022-10-04 Journal: International immunopharmacology [Category] 임상, 치료제, [키워드] ABG, Atrial blood gas Analysis Arbidol assigned Chest CT scans Clinical improvement clinical trial Committee conducted Control control group control groups COVID-19 COVID-2019, Coronavirus Disease 2019 Cox regression model dose effective Effectiveness Efficacy Ethics evaluate GCS, Glasgow Coma Scale hazard Hospitalized hospitalized patient HR, hazard ratio ICU, Intensive care unit Infection injection Intervention intervention group ITT population legally authorized representatives LFT, liver function test median Medical Sciences moderate moderate-severe Mortality non-ICU patient Open-label participant Patient positive positive RT-PCR Prognosis Randomized randomized clinical trial Randomly Ratio receive Registered Result SARS-CoV-2 SARS-CoV-2, severe acute respiratory syndrome coronavirus2 severe COVID-19 Severe patient single-center statistically significant statistically significant difference Subcutaneous time treat treated Treatment treatment group Trial TTCI TTCI, Time to clinical improvement two group umifenovir university VBG, Venous blood gas [DOI] 10.1016/j.intimp.2021.107969 PMC 바로가기 [Article Type] Review
The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials코로나19 환자 사망률에 대한 토실리주맙의 효과: 무작위 대조 시험의 체계적인 검토 및 메타 분석Meta-Analysis Published on 2021-07-012022-09-12 Journal: International immunopharmacology [Category] SARS, 임상, 진단, [키워드] 28-day mortality 95% CI addition Admission AEs assigned benefit clinical Clinical efficacy Cochrane Library control group control groups COVID-19 COVID-19 patient Efficacy and safety eight enrolled Enrollment help ICU ICU admission Infection initial intensive care mechanical ventilation Meta-analysis Mortality no significant difference Patient patients with COVID-19 Placebo Primary outcome randomization Randomized controlled trial RCT RCTs receiving reduce registry risk Safe SARS-CoV-2 searched serious AE Standard of care subgroup analysis survival systematic review Tocilizumab Treatment treatment group treatment-emergent adverse event two group WHO [DOI] 10.1016/j.intimp.2021.107602 PMC 바로가기 [Article Type] Meta-Analysis